Medpace Holdings Stock Performance
MEDP Stock | USD 324.23 4.60 1.44% |
The company secures a Beta (Market Risk) of -0.59, which conveys possible diversification benefits within a given portfolio. As returns on the market increase, returns on owning Medpace Holdings are expected to decrease at a much lower rate. During the bear market, Medpace Holdings is likely to outperform the market. At this point, Medpace Holdings has a negative expected return of -0.0548%. Please make sure to verify Medpace Holdings' treynor ratio, as well as the relationship between the kurtosis and day typical price , to decide if Medpace Holdings performance from the past will be repeated at some point in the near future.
Risk-Adjusted Performance
Very Weak
Weak | Strong |
Over the last 90 days Medpace Holdings has generated negative risk-adjusted returns adding no value to investors with long positions. Even with relatively invariable fundamental indicators, Medpace Holdings is not utilizing all of its potentials. The latest stock price agitation, may contribute to short-term losses for the retail investors. ...more
Actual Historical Performance (%)
One Day Return 1.44 | Five Day Return 0.94 | Year To Date Return (3.14) | Ten Year Return 1.1 K | All Time Return 1.1 K |
1 | Medpace Holdings Inc Shares Up 3.46 percent on Jan 21 | 01/21/2025 |
2 | Clinical Trial Biorepository Archiving Solutions Market Analysis Report 2025-2030, Featuring Medpace, Patheon, Precision Medicine Group, Labcorp Drug Developmen... | 02/06/2025 |
3 | Medpace Holdings, Inc. Shares Sold by Shaker Investments LLC OH | 02/11/2025 |
4 | Medpace Holdings, Inc. Shares Sold by Rice Hall James Associates LLC - MarketBeat | 02/21/2025 |
5 | Disposition of 8127 shares by Carley Brian T of Medpace Holdings at 42.62 subject to Rule 16b-3 | 02/24/2025 |
6 | Medpace Holdings Director Makes a Major Stock Sale - TipRanks | 02/26/2025 |
7 | Acquisition by Stephen Ewald of tradable shares of Medpace Holdings at 326.11 subject to Rule 16b-3 | 02/27/2025 |
8 | Acquisition by Mccarthy Cornelius P. Iii of tradable shares of Medpace Holdings subject to Rule 16b-3 | 02/28/2025 |
9 | Medpace Holdings Insiders Sell US187m Of Stock, Possibly Signalling Caution | 03/04/2025 |
10 | Plato Investment Management Ltd Decreases Stock Holdings in Medpace Holdings, Inc. | 03/06/2025 |
11 | Disposition of 84770 shares by Troendle August J. of Medpace Holdings at 107.93 subject to Rule 16b-3 | 03/07/2025 |
12 | Taika Capital LP Makes New 369,000 Investment in Medpace Holdings, Inc. | 03/10/2025 |
13 | Options Movement At Medpace Hldgs August J Troendle Exercises Worth 95.92M | 03/11/2025 |
14 | Acquisition by Kraft Robert O. of tradable shares of Medpace Holdings subject to Rule 16b-3 | 03/13/2025 |
15 | Contract Research Organization Services Market Is Booming Worldwide 2025-2032 Medpace Holdings, Envigo, MPI Research. | 03/17/2025 |
16 | Medpace Stock Moves -1.04 percent What You Should Know | 03/18/2025 |
Begin Period Cash Flow | 245.4 M |
Medpace |
Medpace Holdings Relative Risk vs. Return Landscape
If you would invest 33,905 in Medpace Holdings on December 22, 2024 and sell it today you would lose (1,482) from holding Medpace Holdings or give up 4.37% of portfolio value over 90 days. Medpace Holdings is currently does not generate positive expected returns and assumes 1.9788% risk (volatility on return distribution) over the 90 days horizon. In different words, 17% of stocks are less volatile than Medpace, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
Risk |
Medpace Holdings Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Medpace Holdings' investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Medpace Holdings, and traders can use it to determine the average amount a Medpace Holdings' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = -0.0277
Best Portfolio | Best Equity | |||
Good Returns | ||||
Average Returns | ||||
Small Returns | ||||
Cash | Small Risk | Average Risk | High Risk | Huge Risk |
Negative Returns | MEDP |
Estimated Market Risk
1.98 actual daily | 17 83% of assets are more volatile |
Expected Return
-0.05 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
-0.03 actual daily | 0 Most of other assets perform better |
Based on monthly moving average Medpace Holdings is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Medpace Holdings by adding Medpace Holdings to a well-diversified portfolio.
Medpace Holdings Fundamentals Growth
Medpace Stock prices reflect investors' perceptions of the future prospects and financial health of Medpace Holdings, and Medpace Holdings fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Medpace Stock performance.
Return On Equity | 0.58 | ||||
Return On Asset | 0.15 | ||||
Profit Margin | 0.19 % | ||||
Operating Margin | 0.23 % | ||||
Current Valuation | 9.19 B | ||||
Shares Outstanding | 30.47 M | ||||
Price To Earning | 49.07 X | ||||
Price To Book | 11.80 X | ||||
Price To Sales | 4.62 X | ||||
Revenue | 2.11 B | ||||
Gross Profit | 1.43 B | ||||
EBITDA | 446.87 M | ||||
Net Income | 404.39 M | ||||
Cash And Equivalents | 31.01 M | ||||
Cash Per Share | 1.00 X | ||||
Total Debt | 126.23 M | ||||
Debt To Equity | 0.85 % | ||||
Current Ratio | 0.41 X | ||||
Book Value Per Share | 27.01 X | ||||
Cash Flow From Operations | 608.82 M | ||||
Earnings Per Share | 12.63 X | ||||
Market Capitalization | 9.74 B | ||||
Total Asset | 2.1 B | ||||
Retained Earnings | 8.17 M | ||||
Working Capital | (75.32 M) | ||||
Current Asset | 94.72 M | ||||
Current Liabilities | 134.02 M | ||||
About Medpace Holdings Performance
Assessing Medpace Holdings' fundamental ratios provides investors with valuable insights into Medpace Holdings' financial health and overall profitability. This information is crucial for making informed investment decisions. A high ROA would indicate that the Medpace Holdings is effectively leveraging its assets and equity to generate significant profits, making it an appealing investment. Conversely, low Return on Assets could signal underlying management issues in assets and equity, indicating a necessity for operational refinements. Please also refer to our technical analysis and fundamental analysis pages.
Last Reported | Projected for Next Year | ||
Return On Tangible Assets | 0.29 | 0.30 | |
Return On Capital Employed | 0.45 | 0.47 | |
Return On Assets | 0.19 | 0.20 | |
Return On Equity | 0.49 | 0.51 |
Things to note about Medpace Holdings performance evaluation
Checking the ongoing alerts about Medpace Holdings for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Medpace Holdings help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.Medpace Holdings generated a negative expected return over the last 90 days | |
Medpace Holdings is unlikely to experience financial distress in the next 2 years | |
Medpace Holdings currently holds 126.23 M in liabilities with Debt to Equity (D/E) ratio of 0.85, which is about average as compared to similar companies. Medpace Holdings has a current ratio of 0.4, indicating that it has a negative working capital and may not be able to pay financial obligations when due. Note, when we think about Medpace Holdings' use of debt, we should always consider it together with its cash and equity. | |
Medpace Holdings has a strong financial position based on the latest SEC filings | |
Over 87.0% of Medpace Holdings shares are owned by institutional investors | |
Latest headline from zacks.com: Medpace Stock Moves -1.04 percent What You Should Know |
- Analyzing Medpace Holdings' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Medpace Holdings' stock is overvalued or undervalued compared to its peers.
- Examining Medpace Holdings' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Medpace Holdings' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Medpace Holdings' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Medpace Holdings' stock. These opinions can provide insight into Medpace Holdings' potential for growth and whether the stock is currently undervalued or overvalued.
Additional Tools for Medpace Stock Analysis
When running Medpace Holdings' price analysis, check to measure Medpace Holdings' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Medpace Holdings is operating at the current time. Most of Medpace Holdings' value examination focuses on studying past and present price action to predict the probability of Medpace Holdings' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Medpace Holdings' price. Additionally, you may evaluate how the addition of Medpace Holdings to your portfolios can decrease your overall portfolio volatility.